This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Diabetic Retinopathy Clinical Research Network | |
|---|---|
| Name | Diabetic Retinopathy Clinical Research Network |
| Formation | 2002 |
| Type | Clinical research network |
| Headquarters | United States |
| Parent organization | National Eye Institute |
Diabetic Retinopathy Clinical Research Network The Diabetic Retinopathy Clinical Research Network is a multicenter clinical research consortium focused on retinal complications of diabetes and related retinal vascular disorders. It coordinates randomized clinical trials, observational studies, and protocol-driven investigations across academic medical centers and community sites to evaluate treatments, imaging modalities, and outcomes. The network links investigators, clinicians, and institutions to accelerate evidence generation for conditions affecting vision in people with Diabetes mellitus and associated retinal disease.
The network operates within a framework involving the National Eye Institute, National Institutes of Health, and partner institutions such as Johns Hopkins Hospital, Mayo Clinic, Massachusetts Eye and Ear, and Wills Eye Hospital. It engages clinical investigators from centers like University of California, San Francisco, Bascom Palmer Eye Institute, University of Pennsylvania Health System, Stanford University Medical Center, and Cleveland Clinic to implement multicenter protocols. The network’s activities intersect with regulatory entities including the Food and Drug Administration and professional societies such as the American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, and American Diabetes Association. Collaborators have included industry partners like Genentech, Regeneron Pharmaceuticals, Novartis, and device manufacturers such as Zeiss and Optovue.
Established in the early 2000s under the aegis of the National Eye Institute and funded through the National Institutes of Health mechanisms, the network was modeled after cooperative groups like the National Cancer Institute networks and the Pediatric Heart Network. Founding investigators were drawn from centers with prior leadership in retinal research, including clinicians affiliated with Henry Ford Health System and University of Wisconsin Hospitals and Clinics; key organizational elements mirror structures used by the Clinical and Translational Science Awards Program and the Global Alliance for Genomics and Health. Governance includes steering committees, protocol committees, and data monitoring boards similar to those in trials sponsored by the Cardiovascular Research Network and the StrokeNet consortium.
The network has conducted landmark randomized trials and observational studies addressing therapies and diagnostics for diabetic retinal disease. Major trials examined intravitreal therapies involving agents developed by Genentech, Regeneron Pharmaceuticals, and Allergan as well as laser modalities promoted by vendors like IRIDEX. Investigations paralleled seminal studies such as the Early Treatment Diabetic Retinopathy Study, the Diabetic Retinopathy Study, and pragmatic trials akin to those from the Veterans Affairs system. Study populations have been recruited from tertiary centers including Columbia University Irving Medical Center, Mount Sinai Hospital (Manhattan), University of Michigan Health System, and community clinics in regions served by Kaiser Permanente.
Protocols emphasize standardized outcome measures, centralized reading centers, and imaging modalities such as spectral-domain optical coherence tomography devices by Heidelberg Engineering, ultrawide-field imaging by Optos, and fluorescein angiography techniques referenced in consensus statements from the American Optometric Association. Statistical design and data management draw on practices used by the Clinical Trials Network and the Pediatric Ophthalmology Collaborative Research Group with data and safety monitoring analogous to procedures from the Data and Safety Monitoring Board frameworks. Ethical oversight involves institutional review boards at participating sites including Yale New Haven Hospital and Duke University Hospital. Protocols often incorporate patient-reported outcome measures developed in collaboration with groups like the National Quality Forum.
Findings have influenced clinical practice guidelines promulgated by bodies such as the American Academy of Ophthalmology and American Diabetes Association, and informed regulatory decisions at the Food and Drug Administration. Results have refined indications for anti-vascular endothelial growth factor therapy, laser photocoagulation, and surgical approaches practiced at centers like Moorfields Eye Hospital and Bascom Palmer Eye Institute. The network’s data contributed to literature cited alongside studies from The Lancet, New England Journal of Medicine, and JAMA and have been discussed at meetings of the Association for Research in Vision and Ophthalmology and the European Society of Retina Specialists.
Primary funding has come from the National Institutes of Health via the National Eye Institute, supplemented by cooperative agreements with industry partners including Genentech, Regeneron Pharmaceuticals, and academic grants from institutions such as Harvard Medical School and Emory University. Collaborative research and data sharing agreements have involved international partners like University College London, Karolinska Institute, and University of Sydney, and philanthropic contributions have come from organizations such as the Lions Clubs International Foundation and disease-focused groups like the Juvenile Diabetes Research Foundation International.
The network supports training of clinician-investigators through mentorship models used at Johns Hopkins University School of Medicine and University of California, Los Angeles David Geffen School of Medicine, and contributes datasets to repositories following standards promoted by the National Library of Medicine and the Global BioData Coalition. Publications appear in journals including Ophthalmology (journal), Retina (journal), Investigative Ophthalmology & Visual Science, and general medical journals such as JAMA and The New England Journal of Medicine, and are presented at conferences like the American Academy of Ophthalmology Annual Meeting and the Association for Research in Vision and Ophthalmology Annual Meeting.
Category:Ophthalmology research organizations